Sidra Medicine Publishes Pediatric Oncology Report 2022

Doha, September 25 (QNA) - Sidra Medicine (a member of Qatar Foundation) has published its "Pediatric Oncology Report 2022" report, sharing the epidemiological data of nearly 400 pediatric patients to give researchers at Sidra Medicine, strong insights into the distribution of the various types of cancers. It also presents the research department’s recruitment and sampling of the eight most prevalent cancer types by year of diagnosis. With a distribution between Hematological (33 per cent) and solid tumors (67 per cent) similar to other countries, the report highlights leukemia (80 per cent) as the most common blood cancer in young patients, while brain tumors (32 per cent) and lymphoma (15 per cent), are the most common types of solid tumors. The report is a synergetic initiative between the research and clinical services at Sidra Medicine to enable personalized medicine strategies for children and young people with cancer. In addition, the report features the multidisciplinary pathways across cancer care and research, and how pathology, genomics, bioinformatics are integrated into the hospital’s specialty services such as oncology hematology, neurosciences, neurosurgery. It also highlights examples of molecular based precision oncology reports on somatic mutations, fusion genes and cancer predisposition. Division Chief of Hematology and Oncology at Sidra Medicine Dr. Ayman Saleh, said: "We firmly believe that our programs will empower pediatric patients to benefit from the seismic shift in cancer treatment, led by targeted and immunotherapy trials. This is what makes pediatric cancer care at our hospital so unique – where diagnosis, care, treatment and finding the best therapies are initiated at the same time." Sidra Medicine recently announced an expansion of its oncology care remit with its pediatric neuro-oncology service for children and young people with malignant brain and spinal cord tumors, details of which can also be found in the 2022 report. (QNA)